Dave Bexfield is the Active MSers guy! I copied this from his newsletter today.
.”FDA Approves Two Oral MS Meds. Last month the U.S. Food and Drug Administration approved Mayzent (siponimod) and Mavenclad (cladribine) tablets to treat relapsing forms of MS and active secondary progressive disease. That makes 17 disease modifying therapies for MS! And why does that matter so dang much? For starters, a new study recently confirmed that the MS prevalence in the US alone is nearly 1 million (release the balloons!), more than doubling earlier estimates. But more importantly, a new large, sweeping MS DMT study in JAMA found that the "risk of reaching major disability milestones has significantly decreased" likely due to "increased use of more efficacious disease-modifying treatments." Keep rereading that sentence. Yes, DMTs matter. A lot.”
.”FDA Approves Two Oral MS Meds. Last month the U.S. Food and Drug Administration approved Mayzent (siponimod) and Mavenclad (cladribine) tablets to treat relapsing forms of MS and active secondary progressive disease. That makes 17 disease modifying therapies for MS! And why does that matter so dang much? For starters, a new study recently confirmed that the MS prevalence in the US alone is nearly 1 million (release the balloons!), more than doubling earlier estimates. But more importantly, a new large, sweeping MS DMT study in JAMA found that the "risk of reaching major disability milestones has significantly decreased" likely due to "increased use of more efficacious disease-modifying treatments." Keep rereading that sentence. Yes, DMTs matter. A lot.”

Comment